INDIANAPOLIS: The report describes the key fact that the mechanism of action of most current and pipeline therapies for Parkinson’s disease is different. Most current therapies focus on neuromodulatory receptors, whereas a majority of pipeline products act in a neuroprotective fashion, targeting and eliminating dysfunctional disease processes…